Merck & Co. Accounts Receivable decreased by 2.8% to $11.78B in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 14.6%, from $10.28B to $11.78B. Over 5 years (FY 2020 to FY 2025), Accounts Receivable shows an upward trend with a 8.4% CAGR.
An increase relative to sales may signal slowing collections or credit risk, while a decrease suggests efficient cash conversion.
The total amount of credit extended to customers and channel partners for products sold or services rendered, minus an a...
Typically scales with revenue growth; however, companies with strong direct-to-consumer channels may have lower receivables relative to those relying on third-party distributors.
accounts_receivable_net| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $7.84B | $8.57B | $9.23B | $9.83B | $9.64B | $9.48B | $9.45B | $10.42B | $11.03B | $10.39B | $10.35B | $11.37B | $11.64B | $11.38B | $10.28B | $10.79B | $11.85B | $12.12B | $11.78B |
| QoQ Change | — | +9.3% | +7.7% | +6.5% | -1.9% | -1.7% | -0.3% | +10.2% | +5.9% | -5.8% | -0.4% | +9.8% | +2.4% | -2.2% | -9.7% | +5.0% | +9.8% | +2.3% | -2.8% |
| YoY Change | — | — | — | — | +23.0% | +10.6% | +2.4% | +6.0% | +14.4% | +9.6% | +9.5% | +9.1% | +5.5% | +9.5% | -0.7% | -5.1% | +1.8% | +6.5% | +14.6% |
We use cookies for analytics. See our Privacy and Cookie Policy.